<DOC>
	<DOCNO>NCT02300532</DOCNO>
	<brief_summary>Post-marketing surveillance investigate clinical safety effectiveness patient implantation Gliadel malignant glioma actual medical setting .</brief_summary>
	<brief_title>Post-Marketing Surveillance Gliadel 7.7mg Implant ( All-case Observational Study )</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Inclusion criterion : Allpatient Gliadel implantation Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Malignant Glioma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
</DOC>